BSG and hepatocellular carcinoma: Indeed, the anti-CD147 drug metuximab (Licartin) prevented tumor recurrence after orthotopic liver transplantation or percutaneous radiofrequency ablation in patients with advanced hepatocellular carcinoma and thus increased the survival rate [103,104].